-
Something wrong with this record ?
Assessment of anthracycline-induced cardiotoxicity with electrocardiography
J.M. Horáček, M. Jakl, J. Horáčková, R. Pudil, L. Jebavý, J. Malý
Language English Country Ukraine
Document type Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't
- MeSH
- Anthracyclines adverse effects MeSH
- Adult MeSH
- Echocardiography MeSH
- Electrocardiography MeSH
- Leukemia drug therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Antineoplastic Agents adverse effects MeSH
- Antineoplastic Combined Chemotherapy Protocols adverse effects MeSH
- Heart drug effects MeSH
- Arrhythmias, Cardiac diagnosis chemically induced MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
AIM: Monitoring of anthracycline-induced cardiotoxicity with electrocardiography (ECG) and comparing ECG changes with findings on echocardiography (ECHO). METHODS: A total of 26 adult acute leukemia patients (mean age 46.2 -/+ 12.4 years, 15 males) treated with 2-6 cycles of anthracycline-based chemotherapy (CT) were studied. Cardiac evaluation was performed at the baseline (before CT), after first CT, after last CT (cumulative anthracycline dose 464.3 -/+ 117.5 mg/m2) and circa 6 months after CT. Time ECG parameters, QRS voltage, presence of repolarization changes, arrhythmias and other abnormalities were evaluated. RESULTS: During treatment and follow-up, we found a statistical significant QTc interval prolongation - 414.7 -/+ 16.0 ms (before CT), 419.6 -/+ 21.6 ms (after first CT), 428.0 -/+ 16.2 ms (after last CT) and 430.1 -/+ 18.4 ms (6 months after CT). Significant QTc interval prolongation (> 450 ms) occurred in 3 patients after first CT, in 4 patients after last CT and in 5 patients within 6 months after CT. Significant total QRS voltage lowering in the limb leads (> 1.0 mV versus before CT) occurred in 3 patients after first CT, in 5 patients after last CT and in 6 patients within 6 months after CT. We found a statistically significant correlation between decreased QRS voltage, QTc interval prolongation and left ventricular (LV) dysfunction on ECHO. Repolarization changes associated with oncology treatment were present in 9 patients within 6 months after CT. CONCLUSION: Anthracycline treatment is associated with changes in electrical activity of the myocardium. Prolonged QTc interval represents a risk for development of malignant ventricular arrhythmias. Decreased QRS voltage and prolonged QTc interval after anthracycline treatment could correlate with LV dysfunction on ECHO. Further studies will be needed to prove whether these ECG changes could serve as an accessible and non-invasive screening method indicating LV dysfunction after anthracycline treatment.
- 000
- 03633naa 2200433 a 4500
- 001
- bmc11019618
- 003
- CZ-PrNML
- 005
- 20221005142057.0
- 008
- 110714s2009 un e eng||
- 009
- AR
- 035 __
- $a (PubMed)19550402
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a un
- 100 1_
- $a Horáček, Jan $7 xx0040415
- 245 10
- $a Assessment of anthracycline-induced cardiotoxicity with electrocardiography / $c J.M. Horáček, M. Jakl, J. Horáčková, R. Pudil, L. Jebavý, J. Malý
- 314 __
- $a Department of Internal Medicine, Faculty of Military Health Sciences, University of Defence, Hradec Kralove 500 01, Czech Republic. jan.hor@post.cz
- 520 9_
- $a AIM: Monitoring of anthracycline-induced cardiotoxicity with electrocardiography (ECG) and comparing ECG changes with findings on echocardiography (ECHO). METHODS: A total of 26 adult acute leukemia patients (mean age 46.2 -/+ 12.4 years, 15 males) treated with 2-6 cycles of anthracycline-based chemotherapy (CT) were studied. Cardiac evaluation was performed at the baseline (before CT), after first CT, after last CT (cumulative anthracycline dose 464.3 -/+ 117.5 mg/m2) and circa 6 months after CT. Time ECG parameters, QRS voltage, presence of repolarization changes, arrhythmias and other abnormalities were evaluated. RESULTS: During treatment and follow-up, we found a statistical significant QTc interval prolongation - 414.7 -/+ 16.0 ms (before CT), 419.6 -/+ 21.6 ms (after first CT), 428.0 -/+ 16.2 ms (after last CT) and 430.1 -/+ 18.4 ms (6 months after CT). Significant QTc interval prolongation (> 450 ms) occurred in 3 patients after first CT, in 4 patients after last CT and in 5 patients within 6 months after CT. Significant total QRS voltage lowering in the limb leads (> 1.0 mV versus before CT) occurred in 3 patients after first CT, in 5 patients after last CT and in 6 patients within 6 months after CT. We found a statistically significant correlation between decreased QRS voltage, QTc interval prolongation and left ventricular (LV) dysfunction on ECHO. Repolarization changes associated with oncology treatment were present in 9 patients within 6 months after CT. CONCLUSION: Anthracycline treatment is associated with changes in electrical activity of the myocardium. Prolonged QTc interval represents a risk for development of malignant ventricular arrhythmias. Decreased QRS voltage and prolonged QTc interval after anthracycline treatment could correlate with LV dysfunction on ECHO. Further studies will be needed to prove whether these ECG changes could serve as an accessible and non-invasive screening method indicating LV dysfunction after anthracycline treatment.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antracykliny $x škodlivé účinky $7 D018943
- 650 _2
- $a protinádorové látky $x škodlivé účinky $7 D000970
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
- 650 _2
- $a srdeční arytmie $x diagnóza $x chemicky indukované $7 D001145
- 650 _2
- $a echokardiografie $7 D004452
- 650 _2
- $a elektrokardiografie $7 D004562
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a srdce $x účinky léků $7 D006321
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a leukemie $x farmakoterapie $7 D007938
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jakl, Martin $7 xx0135493
- 700 1_
- $a Horáčková, Jana. $7 xx0278916
- 700 1_
- $a Pudil, Radek $7 xx0040409
- 700 1_
- $a Jebavý, Ladislav, $d 1950- $7 mzk2007408362
- 700 1_
- $a Malý, Jaroslav, $d 1946- $7 nlk19990073524
- 773 0_
- $t Experimental Oncology $w MED00174402 $g Roč. 31, č. 2 (2009), s. 115-117 $x 1812-9269
- 856 41
- $u https://exp-oncology.com.ua/article/606/assessment-of-anthracycline-induced-cardiotoxicity-with-electrocardiography $y plný text volně přístupný
- 910 __
- $a ABA008 $b x $y 2 $z 0
- 990 __
- $a 20110715114622 $b ABA008
- 991 __
- $a 20221005142052 $b ABA008
- 999 __
- $a ok $b bmc $g 864479 $s 729496
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00174402 $b 31 $c 2 $d 115-117 $i 1812-9269 $m Experimental oncology $n Exp Oncol
- LZP __
- $a 2011-3B09/Bjvme